A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Denintuzumab mafodotin (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results (n=62) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2015 Results (n = 62) published in a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top